TransMedics Group, Inc. (NASDAQ:TMDX) Receives $131.80 Average Target Price from Analysts

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have received a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $131.80.

A number of brokerages recently weighed in on TMDX. Piper Sandler reduced their target price on shares of TransMedics Group from $180.00 to $110.00 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. Needham & Company LLC reaffirmed a “hold” rating and issued a $109.00 target price on shares of TransMedics Group in a research report on Friday, November 22nd. Oppenheimer cut their price target on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. TD Cowen decreased their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Finally, Canaccord Genuity Group dropped their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $86.71 on Friday. TransMedics Group has a 52 week low of $68.84 and a 52 week high of $177.37. The firm has a fifty day moving average of $111.69 and a two-hundred day moving average of $136.16. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock has a market capitalization of $2.91 billion, a price-to-earnings ratio of 92.24 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. During the same quarter last year, the business posted ($0.12) earnings per share. The business’s quarterly revenue was up 63.7% on a year-over-year basis. As a group, equities research analysts predict that TransMedics Group will post 1.01 EPS for the current year.

Insider Activity

In other news, Director Edward M. Basile sold 6,750 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the transaction, the director now directly owns 732 shares in the company, valued at approximately $61,158.60. This represents a 90.22 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the sale, the chief executive officer now owns 61,643 shares in the company, valued at $9,457,269.06. This represents a 12.27 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 26,958 shares of company stock worth $3,470,328. Insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds have recently added to or reduced their stakes in TMDX. Amalgamated Bank raised its stake in shares of TransMedics Group by 6.7% during the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after acquiring an additional 70 shares during the last quarter. Harbour Capital Advisors LLC boosted its holdings in TransMedics Group by 1.7% in the third quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock valued at $760,000 after acquiring an additional 81 shares during the last quarter. Signaturefd LLC increased its position in TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after purchasing an additional 93 shares during the period. Arizona State Retirement System raised its holdings in TransMedics Group by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock worth $1,379,000 after purchasing an additional 186 shares during the last quarter. Finally, Venturi Wealth Management LLC lifted its position in shares of TransMedics Group by 33.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock worth $136,000 after purchasing an additional 219 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.